Pfizer

2026

BIOPHARMACEUTICAL COMMERCIAL STRATEGY

2026 | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

Growth Portfolio &

Commercial Execution Sales Plan

Pfizer

GROWTH PORTFOLIO

COMMERCIAL EXECUTION

GROWTH PRODUCTS

Launched & acquired assets

ONCOLOGY

ADC platform & portfolio

VACCINES

Prevention & access

SPECIALTY CARE

Focused patient pathways

COMMERCIAL MANDATE

Accelerate value from launched and acquired products

through focused customer engagement, market access,

evidence-led adoption and disciplined portfolio execution.

DOCUMENTED Q2 2026 SIGNAL

$3.2B

revenue from launched and acquired products, with

18% operational growth

year over year.

Therapeutic focus: Oncology • Vaccines • Internal Medicine • Inflammation & Immunology • Migraine • Emerging Obesity

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Executive Summary

A focused commercial engine for translating portfolio strength into patient access, product adoption and durable

revenue growth.

Pfizer's 2026 strategy emphasizes maximizing value from key transactions, advancing critical R&D milestones, investing for

post-2028 growth and scaling AI across the business. The commercial plan connects those priorities to launched products,

acquired platforms and future growth opportunities.

$3.2B

Q2 2026 launched & acquired

product revenue

18%

Q2 operational growth of

launched & acquired products

Priority therapeutic areas

highlighted by Pfizer

Pipeline programs as of Aug. 4,

2026

Growth priority

Commercial focus

Outcome to monitor

Launched & acquired

products

Focused field execution and portfolio investment.

Revenue growth / adoption

Oncology

Scale Seagen-derived portfolio and ADC capabilities.

Patient starts / share / indication

expansion

Vaccines

Seasonal and preventive-care engagement.

HCP recommendation / vaccination

uptake

Access

Payer, patient-services and affordability pathways.

Access quality / speed

AI & analytics

Improve customer insight and field-force decision support.

Time to insight / execution quality

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Growth Portfolio

Organize the portfolio around therapeutic areas with distinct commercial motions and lifecycle opportunities.

Portfolio

Commercial focus

Representative growth levers

Oncology

Product adoption, new indications and acquired

Seagen platform.

ADC portfolio, PADCEV, BRAFTOVI, IBRANCE, LORBRENA,

ELREXFIO

Vaccines

Prevention, HCP education and patient access.

Prevnar family, ABRYSVO, Comirnaty and international vaccine

franchises

Internal Medicine

Primary-care and specialty medicines with broad

patient populations.

Eliquis, Vyndaqel family, obesity pipeline

Inflammation &

Immunology

Specialty medicines, biosimilars and emerging

indications.

Lifecycle expansion, access and evidence

Migraine

Expand treatment options and patient

identification.

NURTEC portfolio, additional indications

Obesity

Build a future commercial platform around Metsera

assets.

Berobenatide, market access, patient journey readiness

Hospital

Hospital-based and specialty medicines.

Institutional access, formulary engagement, care pathways

Portfolio principle: allocate commercial intensity according to growth opportunity, evidence, access conditions, lifecycle stage

and customer need.

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Target Customers & Markets

Connect healthcare stakeholders through a common commercial pathway from clinical need to treatment access.

Customer

Clinical / business need

Commercial engagement

Access bridge

Physicians

Evidence, treatment choice, patient fit

Scientific exchange, field

engagement

Coverage and prescribing support

Specialists

Disease-specific evidence and patient

identification

Specialty field teams

Payer / specialty pharmacy

coordination

Hospitals & health

systems

Outcomes, formulary value, care

pathways

Account management

Contracting / formulary / distribution

Pharmacies

Dispensing continuity and product

availability

Channel engagement

Distribution / benefit pathway

Payers

Evidence, value and budget impact

Market access teams

Coverage / contracting / policy

Government

programs

Population health and affordability

Government account teams

Program requirements

Patients

Awareness, affordability and continuity

Patient services / digital

Support, access and adherence

pathways

CUSTOMER

CLINICAL NEED

PRODUCT

ACCESS

ADOPTION

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Oncology Sales Strategy

Scale an increasingly differentiated oncology portfolio through evidence, indication expansion, access and specialist

engagement.

Commercial pillar

Execution model

Key measures

ADC platform

Translate platform science into differentiated product positioning.

HCP reach / new starts

In-line growth

Support established products with focused field and account execution.

Revenue / share / persistence

Indication expansion

Prepare HCPs and systems for newly approved or expanding uses.

New-indication adoption

Patient identification

Improve identification of appropriate patients through data and clinical

pathways.

Eligible patients / starts

Market access

Align evidence, payer value and distribution with treatment pathways.

Coverage / access speed

Portfolio expansion

Use oncology platforms and pipeline readouts to extend franchise depth.

Launch readiness / pipeline conversion

Documented Q2 2026 signal:

Pfizer reported 21% year-over-year U.S. growth for the legacy Seagen portfolio after excluding

a one-time prior-year stocking benefit.

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Vaccine Commercial Strategy

Build preventive-care demand through seasonal readiness, HCP education, access and public-health channels.

Franchise / focus

Commercial motion

Demand driver

Prevnar family

Pediatric and adult vaccination engagement, depending on market.

Routine and risk-based prevention

ABRYSVO

HCP and patient education around RSV prevention.

Seasonal vaccination demand

Comirnaty

Seasonal readiness and evidence-based vaccination engagement.

COVID-19 vaccination season

International vaccines

Adapt commercial programs to local public-health systems.

Market-specific access and seasonality

Future vaccine pipeline

Launch preparation and stakeholder education.

New prevention opportunities

Vaccine execution cycle

SEASONAL PLAN

HCP EDUCATION

ACCESS

PATIENT ACTION

UPTAKE

Commercial teams should align inventory, channel readiness, payer dynamics and HCP communication before peak

vaccination periods.

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

New Growth Opportunities

Use recent transactions and pipeline assets to establish the next wave of commercial growth.

Opportunity

Strategic role

Commercial preparation

Obesity / Metsera

Build a new high-growth therapeutic platform.

Market access capability, patient journey, payer strategy,

launch readiness

Berobenatide

Advance an investigational monthly GLP-1 program

through Phase 3 development.

Evidence generation, future positioning, access planning

Migraine / Biohaven

Expand a dedicated migraine treatment platform.

Patient identification, treatment adoption, lifecycle

opportunities

Oncology / Seagen

Expand ADC and acquired oncology franchises.

Indication expansion, specialist engagement, account

strategy

AI-enabled commercial

Use data and AI to improve insight and execution.

Analytics, decision support, field effectiveness

MET SERA

Obesity & cardiometabolic

BIOHAVEN

Migraine platform

SEAGEN

Oncology & ADC

Pfizer completed its Metsera acquisition in November 2025 and identifies the transaction as a major obesity growth platform; Pfizer also describes

Biohaven as strengthening its migraine opportunity.

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Commercial Execution Model

A patient-centered commercial sequence connecting opportunity identification with access, adoption and

continuation.

MARKET OPPORTUNITY

CUSTOMER ID

PATIENT ID

HCP ENGAGEMENTMARKET ACCESS

ADOPTION

CONTINUATION

EXPANSION

Execution layer

Core activity

Data / decision signal

Market opportunity

Map disease burden, competitive environment and unmet

need.

Market size / growth / unmet need

Customer identification

Segment HCPs, accounts, payers and systems.

Potential / behavior / access

Patient identification

Support appropriate patient identification through data and

clinical pathways.

Eligible population / diagnosis

HCP engagement

Deliver relevant clinical information and evidence.

Reach / frequency / response

Market access

Coordinate payer, affordability, distribution and patient

services.

Coverage / access speed

Product adoption

Monitor starts, utilization and appropriate use.

New starts / share

Treatment continuation

Support persistence and duration where clinically appropriate.

Continuation / refill

Portfolio expansion

Translate evidence and lifecycle milestones into new

opportunities.

Indications / populations

Pfizer's Q2 2026 management commentary described commercial teams as focused on identifying patients, enabling access

and supporting duration of therapy based on clinical data.

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Product Launch & Market Expansion

A lifecycle framework for preparing, launching, scaling and expanding priority products.

Lifecycle

Commercial priorities

Key deliverables

Pre-Launch

Market assessment, segmentation and access planning.

Customer map, evidence narrative, access

plan

Launch

HCP engagement, patient awareness, access and distribution.

Field readiness, account plan, channel

readiness

Post-Launch

Adoption monitoring and customer feedback.

Performance dashboard, optimization plan

Expansion

New indications, geographies and patient populations.

Lifecycle plan, evidence and access

updates

Growth

Portfolio expansion and treatment continuation.

Retention plan, new patient opportunities

Launch governance

MEDICAL

COMMERCIAL

ACCESS

SUPPLY

ANALYTICS

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Commercial Organization & Sales Execution

Coordinate U.S. and international commercial capabilities with medical, access, analytics and digital support.

Organization / capability

Primary role

Commercial connection

Pfizer U.S. Commercial

Primary care, specialty care and oncology execution.

Brand, field and account strategy

International Commercial

Adapt portfolio strategy across international markets.

Local market execution and access

Field force

Engage HCPs and accounts with relevant evidence.

Reach, frequency and execution quality

Marketing

Translate product value into customer journeys.

Segmentation, messaging, campaigns

Medical Affairs

Support scientific exchange and evidence generation.

Clinical confidence and appropriate use

Market Access

Develop payer value, contracting and access

strategies.

Coverage and affordability

Data & Analytics

Turn customer and market data into decisions.

Targeting, performance and insights

AI-enabled support

Scale tools that improve decision speed and field

effectiveness.

Insight generation and workflow efficiency

Pfizer's 2026 strategic priorities explicitly include scaling AI across the business. Current Pfizer commercial analytics roles

also describe AI-enabled tools being used to accelerate the path from data to decision and connect brand strategy, patient

access and business performance.

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Sales KPIs & Growth Metrics

Use documented business performance alongside operational commercial indicators; avoid treating public results as

internal sales quotas.

KPI group

Metric

Management use

Portfolio

Revenue growth

Measure growth contribution by portfolio and therapeutic area.

Portfolio

Launched / acquired product growth

Track performance of growth platforms.

Portfolio

Product adoption

Monitor uptake after launch or indication expansion.

Customer

HCP reach & engagement

Assess field-force effectiveness.

Access

Coverage / access quality

Monitor ability to reach eligible patients.

Launch

Launch performance

Track readiness, uptake and early trajectory.

Patient

New patient starts

Measure treatment initiation where appropriate.

Patient

Treatment continuation

Monitor duration / persistence where clinically relevant.

Market

Market share

Assess competitive position by category.

Business

Cost efficiency

Balance commercial investment with growth.

Pipeline

Pipeline-to-commercial transition

Track readiness for future launches.

18%

Q2 2026 operational growth in launched &

acquired products

21%

Q2 U.S. growth of legacy Seagen portfolio,

excluding prior-year stocking benefit

$3.2B

Q2 revenue from launched & acquired

products

PFIZER | GROWTH PORTFOLIO & COMMERCIAL EXECUTION

2026 Commercial Strategy

Pfizer Commercial Growth Framework

A single operating chain linking science, healthcare customers, patient access and portfolio growth.

Growth Portfolio

Prioritize launched, acquired and emerging assets.

Market Opportunity

Map disease burden, competitive dynamics and unmet need.

Customer & Patient

Identification

Target relevant HCPs, accounts and appropriate patient populations.

HCP Engagement

Deliver evidence-led information and support clinical decision-making.

Market Access

Align payer, affordability, distribution and patient-services pathways.

Product Launch &

Adoption

Convert evidence and access into appropriate treatment uptake.

Treatment Continuation

Support clinically appropriate duration and patient experience.

Portfolio Expansion

Use new indications, populations, geographies and platforms to extend growth.

Revenue Growth

Measure commercial contribution and reinvest behind future growth.

Commercial north star:

Pfizer Growth Portfolio

→

Target Healthcare Markets

→

Commercial Execution

→

Market Access

→

Product Adoption

→

Portfolio Expansion

→

Revenue Growth

Documented 2026 figures in this plan reflect public Pfizer disclosures available through Q2 2026; operational commercial targets should be refreshed as

subsequent company reporting becomes available.

Pfizer Growth Portfolio & Commercial Execution Sales Plan

Prompt to Clone This Pfizer Growth Portfolio & Commercial Execution Sales Plan

Apply this example's core structure, strategic pacing, and structural hierarchy directly to your own topic.

What are you generating today?